The Flaws With IPR Patent Review: Acorda CEO Weighs In On Allergan Move

Allergan’s unusual arrangement to try to avoid IPR proceedings on Restasis made headlines last week. Our article suggesting the move is potentially damaging for the image of the biopharma sector as a whole prompted a response from Acorda CEO Ron Cohen.